|
1
|
Ghia P, Ferreri AM and Caligaris-Cappio F:
Chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 64:234–246.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giannopoulos K: Biologia i rokowanie w
przewlekłej białaczce limfocytowej. Acta Haematol Pol. 41:433–440.
2010.
|
|
3
|
Zenz T, Mertens D, Döhner H and
Stilgenbauer S: Importance of genetics in chronic lymphocytic
leukemia. Blood Rev. 25:131–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuckertz M, Patz M, Veldurthy A, Gehrke I,
Claasen J, Frenzel LP, Wendtner CM, Hallek M and Krause G:
Comparison of the effects of two kinase inhibitors, sorafenib and
dasatinib, on chronic lymphocytic leukemia cells. Onkologie.
35:420–426. 2012.PubMed/NCBI
|
|
5
|
Stevenson FK and Caligaris-Cappio F:
Chronic lymphocytic leukemia: Revelations from the B-cell receptor.
Blood. 103:4389–4395. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amrein PC: The potential for dasatinib in
treating chronic lymphocytic leukemia, acute myeloid leukemia, and
myeloproliferative neoplasms. Leuk Lymphoma. 52:754–763. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Winiarska M, Bojarczuk K, Pyrzynska B, Bil
J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P,
Zagozdzon A, et al: Inhibitors of SRC kinases impair antitumor
activity of anti-CD20 monoclonal antibodies. MAbs. 6:1300–1313.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCaig AM, Cosimo E, Leach MT and Michie
AM: Dasatinib inhibits B cell receptor signalling in chronic
lymphocytic leukaemia but novel combination approaches are required
to overcome additional pro-survival microenvironmental signals. Br
J Haematol. 153:199–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amrein L, Hernandez TA, Ferrario C,
Johnston J, Gibson SB, Panasci L and Aloyz R: Dasatinib sensitizes
primary chronic lymphocytic leukaemia lymphocytes to chlorambucil
and fludarabine in vitro. Br J Haematol. 143:698–706. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Contri A, Brunati AM, Trentin L, Cabrelle
A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G and
Donella-Deana A: Chronic lymphocytic leukemia B cells contain
anomalous Lyn tyrosine kinase, a putative contribution to defective
apoptosis. J Clin Invest. 115:369–378. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gobessi S, Laurenti L, Longo PG, Sica S,
Leone G and Efremov DG: ZAP-70 enhances B-cell-receptor signaling
despite absent or inefficient tyrosine kinase activation in chronic
lymphocytic leukemia and lymphoma B cells. Blood. 109:2032–2039.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin K, Glenn MA, Harris RJ, Duckworth AD,
Dennett S, Cawley JC, Zuzel M and Slupsky JR: c-Abl expression in
chronic lymphocytic leukemia cells: Clinical and therapeutic
implications. Cancer Res. 66:7801–7809. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hochhaus A, Kantarjian HM, Baccarani M,
Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes
F, Niederwieser D, et al: Dasatinib induces notable hematologic and
cytogenetic responses in chronic-phase chronic myeloid leukemia
after failure of imatinib therapy. Blood. 109:2303–2309. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McCaig AM, Cosimo E, Leach MT and Michie
AM: Dasatinib inhibits CXCR4 signaling in chronic lymphocytic
leukaemia cells and impairs migration towards CXCL12. PLoS One.
7:e489292012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Amrein L, Soulières D, Johnston JB and
Aloyz R: p53 and autophagy contribute to dasatinib resistance in
primary CLL lymphocytes. Leuk Res. 35:99–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hallaert DYH, Jaspers A, van Noesel CJ,
van Oers MH, Kater AP and Eldering E: c-Abl kinase inhibitors
overcome CD40-mediated drug resistance in CLL: Implications for
therapeutic targeting of chemoresistant niches. Blood.
112:5141–5149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kater AP, Spiering M, Liu RD, Doreen Te
Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK,
Lankheet NA, et al: Dasatinib in combination with fludarabine in
patients with refractory chronic lymphocytic leukemia: A
multicenter phase 2 study. Leuk Res. 38:34–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
ten Hacken E, Scielzo C, Bertilaccio MTS,
Scarfò L, Apollonio B, Barbaglio F, Stamatopoulos K, Ponzoni M,
Ghia P and Caligaris-Cappio F: Targeting the LYN/HS1 signaling axis
in chronic lymphocytic leukemia. Blood. 121:2264–2273. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giannopoulos K, Dmoszynska A, Kowal M,
Wasik-Szczepanek E, Bojarska-Junak A, Rolinski J, Döhner H,
Stilgenbauer S and Bullinger L: Thalidomide exerts distinct
molecular antileukemic effects and combined thalidomide/fludarabine
therapy is clinically effective in high-risk chronic lymphocytic
leukemia. Leukemia. 23:1771–1778. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lombardo LJ, Lee FY, Chen P, Norris D,
Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko
AM, et al: Discovery of
N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor
activity in preclinical assays. J Med Chem. 47:6658–6661. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martinez Marignac VL, Smith S, Toban N,
Bazile M and Aloyz R: Resistance to Dasatinib in primary chronic
lymphocytic leukemia lymphocytes involves AMPK-mediated energetic
re-programming. Oncotarget. 4:2550–2566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amrein PC, Attar EC, Takvorian T, Hochberg
EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand
P, et al: Phase II study of dasatinib in relapsed or refractory
chronic lymphocytic leukemia. Clin Cancer Res. 17:2977–2986. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hochhaus A, Baccarani M, Silver RT,
Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE,
Deininger MW, Guilhot F, et al: European LeukemiaNet 2020
recommendations for treating chronic myeloid leukemia. Leukemia.
34:966–984. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Putowski M, Podgórniak M, Piróg M, Knap J,
Zaleska J, Purkot J, Zawiślak J, Zakrzewska E, Karczmarczyk A,
Własiuk P, et al: Prognostic impact of NOTCH1, MYD88, and SF3B1
mutations in Polish patients with chronic lymphocytic leukemia. Pol
Arch Intern Med. 127:238–244. 2017.PubMed/NCBI
|
|
25
|
Bojarska-Junak A, Giannopoulos K, Kowal M,
Dmoszyńska A and Roliński J: Comparison of methods for determining
zeta-chain associated protein-70 (ZAP-70) expression in patients
with B-cell chronic lymphocytic leukemia (B-CLL). Cytometry B Clin
Cytom. 70:293–301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burger JA and O'Brien S: Evolution of CLL
treatment-from chemoimmunotherapy to targeted and individualized
therapy. Nat Rev Clin Oncol. 15:510–527. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dühren-von Minden M, Übelhart R, Schneider
D, Wossning T, Bach MP, Buchner M, Hofmann D, Surova E, Follo M,
Köhler F, et al: Chronic lymphocytic leukaemia is driven by
antigen-independent cell-autonomous signalling. Nature.
489:309–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Veldurthy A, Patz M, Hagist S, Pallasch
CP, Wendtner CM, Hallek M and Krause G: The kinase inhibitor
dasatinib induces apoptosis in chronic lymphocytic leukemia cells
in vitro with preference for a subgroup of patients with unmutated
IgVH genes. Blood. 112:1443–1452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pitini V, Arrigo C and Altavilla G:
Dasatinib induces a response in chronic lymphocytic leukemia.
Blood. 113:4982009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garg RJ, Wierda W, Fayad L, Estrov Z,
Bickel SM and O'Brien S: Phase II study of dasatinib in patients
with relapsed CLL. Blood. 112:4197a2008. View Article : Google Scholar
|
|
31
|
Song Z, Lu P, Furman RR, Leonard JP,
Martin P, Tyrell L, Lee FY, Knowles DM, Coleman M and Wang YL:
Activities of SYK and PLCgamma2 predict apoptotic response of CLL
cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res.
16:587–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hantschel O, Rix U, Schmidt U,
Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL,
Ellmeier W, Valent P, et al: The Btk tyrosine kinase is a major
target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA.
104:13283–13288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Serpa M, Bendit I, Seguro F, Xavier F,
Cavalcante M, Steinbaum D, Nardinelli L, Aldred VL, de Paula HM and
Dorlhiac-Llacer PE: Response to dasatinib in a patient with
concomitant chronic myeloid leukemia and chronic lymphocytic
leukemia. Acta Haematol. 124:105–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim DH, Kamel-Reid S, Chang H, Sutherland
R, Jung CW, Kim HJ, Lee JJ and Lipton JH: Natural killer or natural
killer/T cell lineage large granular lymphocytosis associated with
dasatinib therapy for Philadelphia chromosome positive leukemia.
Haematologica. 94:135–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mustjoki S, Ekblom M, Arstila TP, Dybedal
I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M,
Kovanen P, Laurinolli T, et al: Clonal expansion of T/NK-cells
during tyrosine kinase inhibitor dasatinib therapy. Leukemia.
23:1398–1405. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsimberidou AM, Wen S, McLaughlin P,
O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ,
Kantarjian HM, et al: Other malignancies in chronic lymphocytic
leukemia/small lymphocytic lymphoma. J Clin Oncol. 27:904–910.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Benjamini O, Jain P, Trinh L, Qiao W,
Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, et
al: Second cancers in patients with chronic lymphocytic leukemia
who received frontline fludarabine, cyclophosphamide and rituximab
therapy: Distribution and clinical outcomes. Leuk Lymphoma.
56:1643–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boddu P, Gibbons J, Burger J, Sivina M,
Thakral B, Kanagal-Shamanna R and Ferrajoli A: Co-occurrence of
chronic myeloid leukemia with chronic lymphocytic leukemia: A
report of two cases. Leuk Lymphoma. 60:1568–1571. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fischer K, Bahlo J, Fink AM, Goede V,
Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A,
Maurer C, et al: Long-term remissions after FCR chemoimmunotherapy
in previously untreated patients with CLL: Updated results of the
CLL8 trial. Blood. 127:208–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tecchio C, Nichele I, Todeschini G,
Pizzolo G and Ambrosetti A: Dasatinib-induced response in a rare
case of chronic lymphocytic leukaemia associated with chronic
myeloid leukaemia. Br J Haematol. 146:222–223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nagao T, Takahashi N, Kameoka Y, Noguchi
S, Shinohara Y, Ohyagi H, Kume M and Sawada K: Dasatinib-responsive
chronic lymphocytic leukemia in a patient treated for coexisting
chronic myeloid leukemia. Intern Med. 52:2567–2571. 2013.
View Article : Google Scholar : PubMed/NCBI
|
